Cargando…
Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
With the gradual improvement of treatment regimens, the survival time of multiple myeloma (MM) patients has been significantly prolonged. Even so, MM is still a nightmare with an inferior prognosis. B-cell maturation antigen (BCMA) is highly expressed on the surface of malignant myeloma cells. For t...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936073/ https://www.ncbi.nlm.nih.gov/pubmed/35320942 http://dx.doi.org/10.3389/fimmu.2022.839097 |